News

FDA names Dr. Vinay Prasad as top vaccine official
In his new role with the FDA, Dr. Vinay Prasad will oversee the regulation of costly drugs, including vaccines, gene ...
Le Lézard5d
Biocon Biologics Secures Strong Market Access Coverage for Yesintektm in the United States Covering 100+ Million Lives
Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), today announced the Company has secured multiple market access ...
Korea JoongAng Daily on MSN5d
Korean firms 'exploring options' as Trump's pharma tariffs loom
Tensions rise in Korea's pharma sector as Trump plans drug tariffs. Companies like Samsung Biologics monitor the situation ...
WLNS.com25d
Biocon Biologics Secures Market Entry Date for Yesafili™, an Interchangeable Biosimilar to Eylea®, in the U.S.
BRIDGEWATER, N.J. and BENGALURU, Karnataka, India, April 15, 2025 /PRNewswire/ -- Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd (BSE code ...
Yahoo Finance18d
Samsung Biologics reports first quarter 2025 financial results
Samsung Biologics Logo (PRNewsfoto/Samsung Biologics ... "The launch of Plant 5 and our dedicated antibody-drug conjugate (ADC) facility marks another milestone in expanding our capacity to cater to ...
Finanznachrichten25d
Biocon Biologics Ltd.: Biocon Biologics Secures Market Entry Date for Yesafili, an Interchangeable Biosimilar to Eylea, in the U.S.
BRIDGEWATER, N.J. and BENGALURU, Karnataka, India, April 15, 2025 /PRNewswire/ -- Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd (BSE code ...
Le Lézard9d
Edwards TAVR Receives FDA Approval for Patients With Asymptomatic Severe Aortic Stenosis
Edwards Lifesciences announced today that the U.S. Food and Drug Administration (FDA) has approved its transcatheter aortic valve replacement (TAVR) therapy, the SAPIEN 3 platform, for severe aortic ...